Menu Search
Equities

Boule Diagnostics AB

BOUL:STO

Boule Diagnostics AB

Actions
Health CareMedical Equipment and Services
  • Price (SEK)6.78
  • Today's Change-0.52 / -7.12%
  • Shares traded57.40k
  • 1 Year change-27.87%
  • Beta0.4946
Data delayed at least 15 minutes, as of Nov 12 2024 17:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy0
Outperform1
Hold0
Sell0
Strong Sell0

Share price forecast in SEK

The one analyst offering a 12 month price target expects Boule Diagnostics AB share price to rise to 87.00 in the next year from the last price of 6.78.
High1,183.2%87.00
Med1,183.2%87.00
Low1,183.2%87.00

Dividends

Historical dividend information is not available for Boule Diagnostics AB.
Div growth (TTM)--
More ▼

Earnings history & estimates in SEK

On Oct 25, 2024, Boule Diagnostics AB reported 3rd quarter 2024 losses of -5.90 per share. This result exceeded the -7.75 consensus loss of the one analyst covering the company and under-performed last year's 3rd quarter results by -6.02.
The next earnings announcement is expected on Feb 11, 2025.
Average growth rate-4,851.01%
Boule Diagnostics AB reported annual 2023 earnings of 0.64 per share on Feb 06, 2024.
Average growth rate-1.71%
More ▼

Revenue history & estimates in SEK

Boule Diagnostics AB (publ) had 3rd quarter 2024 revenues of 130.40m. This missed the 131.50m consensus estimate of the 2 analysts following the company. This was 8.87% below the prior year's 3rd quarter results.
Average growth rate-1.56%
Boule Diagnostics AB (publ) had revenues for the full year 2023 of 571.30m. This was 4.23% above the prior year's results.
Average growth rate+4.62%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.